The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: Results from two pilot rounds show room for optimization

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Tembuyser, Lien ^a   Tack, Vé Ronique ^a   Zwaenepoel, Karen ^b   Pauwels, Patrick ^b   Miller, Keith ^c   Bubendorf, Lukas ^d   Kerr, Keith ^e   Schuuring, Ed ^f   Thunnissen, Erik ^g   Dequeker, Elisabeth M C ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UKNEQAS ICC and ISH   (United Kingdom)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ALK GENE; ARTICLE; DIAGNOSTIC ERROR; DISEASE MARKER; EXTERNAL VALIDITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GOOD LABORATORY PRACTICE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MOLECULAR DIAGNOSIS; NON SMALL CELL LUNG CANCER; PILOT STUDY; PREDICTION; QUALITY CONTROL; TISSUE MICROARRAY; TREATMENT RESPONSE; VALIDATION PROCESS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; HEALTH CARE QUALITY; LABORATORY; LUNG NEOPLASMS; PATHOLOGY; STANDARDS;

CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORIES; LUNG NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84912006579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112159     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Cagle PT, Allen TC, Olsen RJ (2013) Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med 137: 1191-1198.
3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
4. Stinchcombe TE, Socinski MA (2008) Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? Oncologist 13: 933-944.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
6. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small- cell lung cancer: recent developments. Lancet 382: 709-719.
7. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
8. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, et al. (2008) Identification of novel isoforms of the EML4-ALK transforming gene in nonsmall cell lung cancer. Cancer Res 68: 4971-4976.
9. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, et al. (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149.
10. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
11. Dacic S (2013) Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol 66: 870-874.
12. Mino-Kenudson M, Mark EJ (2011) Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med 135: 655-664.
13. Sasaki T, Janne PA (2011) New strategies for treatment of ALK-rearranged nonsmall cell lung cancers. Clin Cancer Res 17: 7213-7218.
14. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, et al. (2012) EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 461: 245-257.
15. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 15: 415-453.
16. Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, et al. (2014) On the relevance of a testing algorithm for the detection of ROS1- rearranged lung adenocarcinomas. Lung Cancer 83: 168-173.
17. Thunnissen E, van der Oord K, den Bakker M (2014) Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 464: 347-358.
18. Deans ZC, Bilbe N, O'Sullivan B, Lazarou LP, de Castro DG, et al. (2013) Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment. J Clin Pathol 66: 319-325.
19. van Krieken JH, Normanno N, Blackhall F, Boone E, Botti G, et al. (2013) Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 462: 27-37.
20. International Organization for Standardization (2012) ISO 15189: 2012 Medical laboratories - Particular requirements for quality and competence. Geneva, ISO.
21. Gulley ML, Braziel RM, Halling KC, Hsi ED, Kant JA, et al. (2007) Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med 131: 852-863.
22. Thunnissen E, Bovee JV, Bruinsma H, van den Brule AJ, Dinjens W, et al. (2011) EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. J Clin Pathol 64: 884-892.
23. Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, et al. (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299-307.
24. Garrido P, de Castro J, Concha A, Felip E, Isla D, et al. (2012) Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol 14: 338-349.
25. Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, et al. (2013) Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol26: 1545-1553.
26. Zwaenepoel K, Van Dongen A, Lambin S, Weyn C, Pauwels P (2014) Detection of ALK expression in NSCLC with ALK-gene rearrangements - comparison of multiple IHC methods. Histopathology. In press.
27. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, et al. (2012) Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 18: 4682-4690.
28. Crystal AS, Shaw AT (2012) Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer? Clin Cancer Res 18: 4479-4481.
29. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, et al. (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16: 5581-5590.
30. Yoshida A, Tsuta K, Nitta H, Hatanaka Y, Asamura H, et al. (2011) Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 6: 1677-1686.
31. Han XH, Zhang NN, Ma L, Lin DM, Hao XZ, et al. (2013) Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small- cell lung cancer. Virchows Arch 463: 583-591.
32. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, et al. (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8: 45-51.
33. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16: 1561-1571.
34. Cabillic F, Gros A, Dugay F, Begueret H, Mesturoux L, et al. (2014) Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances. J Thorac Oncol 9: 295-306.
35. Nordic Immunohistochemical Quality Control. Lung Anaplastic Lymphoma Kinase Assessment Run 39 2013. Available: http://www.nordiqc.org/Run-39- B16-H4/Assessment/Run39-ALK.pdf. Accessed 2014 Apr 1.
36. Blackhall FH, Peters S, Bubendorf L, Dafni U, Hager H, et al. (2014) Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 32: 2780-2787.
37. Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken JH, et al. (2014) Higher Quality of Molecular Testing, an Unfulfilled Priority: Results from External Quality Assessment for KRAS Mutation Testing in Colorectal Cancer. J Mol Diagn 16: 371-377.